90% reduction in COVID-19 deaths after booster dose: Hong Kong study
Newswise — A booster (third) dose of the SARS-CoV-2 vaccine reduces mortality by 90% in people with multiple health conditions compared to two doses, according to a new study published in Hong Kong decreased. CMAJ (Journal of the Canadian Medical Association) https://www.cmaj.ca/lookup/doi/10.1503/cmaj.221068.
“We found that the risk of COVID-19-related death was significantly reduced in adults with multimorbidity who received allogeneic boosters of BNT162b2, an mRNA vaccine, or CoronaVac, an inactivated whole virus vaccine,” said Dr. Esther. Chan, Li Ka wrote. Co-author, Singh School of Medicine, University of Hong Kong and Health Data Exploration Institute, Hong Kong. “These results confirm the effectiveness of boosting vaccines from two different technology platforms in reducing mortality among people with multiple diseases in an Omicron outbreak.”
When an outbreak of the Omicron (BA.2) variant hit Hong Kong in late 2021, the city reported the highest COVID-19 death rate in the world compared to a population of 7.5 million. After November 11, 2021, older adults, health professionals, and other priority groups should receive a BNT162b2 mRNA (Fosun-BioNTech, equivalent to Pfizer-BioNTech outside of China) or CoronaVac (Sinovac) vaccine booster. is ready. As of January 1, 2022, everyone else is eligible, and in his first four months of 2022, he received over 3 million boosters.
“Our findings suggest that this timely and large-scale public health response has a crucial role to play in reducing mortality in this epidemic, especially for people with multiple comorbidities. ,” writes lead author Francisco Lai, a scientist at the Li Ka Shing Department. Co-authored with the University of Hong Kong School of Medicine and the Hong Kong Health Data Exploration Institute.
Researchers had two or more chronic conditions such as hypertension, diabetes, or chronic kidney disease who received a booster (third dose) between November 11, 2021 and March 31, 202218 We compared the data of people over the age of 10. For those who received it only twice. The study included 120,724 recipients of the Pfizer-BioNTech vaccine (87,289 boosters) and 127,318 CoronaVac recipients (94,977 boosters). There were more deaths in CoronaVac recipients than in Pfizer-BioNTech recipients.
The results of this study “underscore the potential benefits of booster vaccination, especially in vulnerable populations living with multimorbidity, and suggest future booster doses of SARS-CoV-2 vaccines after the first booster.” confirms our recent focus on the elderly and those with chronic diseases.”
The robust results contribute to the evidence base that receiving a boost offers strong protection against death from COVID-19.
“The data on SARS-CoV-2 vaccination records used in this study were provided by the sole operator of vaccine deployment in Hong Kong and were linked to a unified record system and provided by Public Health across the region. We have a clinical record.For healthcare providers, our data should be reliable and representative,” the authors conclude.
